Alexandria Real Estate Equities, Inc.

AI-generated fair value estimate for this company.

Method: 10-year FFO-per-share DCF: $6.40/share 2026 company FFO guidance as base; growth 2-2.5% yrs1-5, 3% yrs6-10; 11% discount rate (elevated for life-science real estate oversupply/tenant-credit risk); 2.5% terminal growth; 174.25M shares outstanding; not separately adjusted for $13.168B debt since FFO is already a levered per-share metric.

Reasoning: Alexandria is a AAA life-science REIT trading at a depressed roughly 8x forward FFO (vs. historical 18-22x) due to lab-space oversupply and softer biotech tenant demand (reflected in a TTM GAAP net loss from impairments); the elevated discount rate and modest growth path reflect real risk of continued oversupply pressure while still crediting FFO durability.